Core Insights - 16 dividend growth companies announced increases in the second half of April, indicating a positive trend in dividend policies among these firms [1] - Predictions are made for an additional 7 companies expected to announce dividend increases in the first half of May, suggesting ongoing confidence in dividend growth [1] Group 1 - The article highlights the effectiveness of investing in dividend growth stocks and reinvesting dividends as a strategy for long-term wealth growth [1] - The author operates a blog, HarvestingDividends.com, which focuses on S&P Dividend Aristocrats and other dividend growth stocks, providing valuable insights for investors [1]

Financial Performance Highlights - Net income attributable to Unitholders for the three months ended March 31, 2025, was $80 million ($0.38 per limited partnership unit), compared to $48 million ($0.23 per limited partnership unit) in the prior period[12, 19] - Adjusted EBITDA for the three months ended March 31, 2025, was $591 million, compared to $544 million in the prior period[12, 19] - Adjusted EFO for the three months ended March 31, 2025, was $345 million ($1.60 per unit), compared to $331 million ($1.53 per unit) in the prior period[19] - Corporate liquidity as of March 31, 2025, was $2,414 million, including $59 million of cash and liquid securities and $2,330 million of availability on credit facilities[19, 24] Segment Performance - Business Services Adjusted EBITDA was $213 million, compared to $205 million in the prior period[13, 45] - Infrastructure Services Adjusted EBITDA was $104 million, compared to $143 million in the prior period, which included contribution from the shuttle tanker operation in offshore oil services that was sold in January 2025[13, 49] - Industrials Adjusted EBITDA was $304 million, compared to $228 million in the prior period, with the advanced energy storage operation contributing $233 million compared to $159 million in the prior period[13, 54] Balance Sheet and Liquidity - Total assets as of March 31, 2025, were $75,887 million, compared to $75,474 million as of December 31, 2024[23] - Non-recourse borrowings in subsidiaries were $42,316 million as of March 31, 2025, compared to $36,720 million as of December 31, 2024[23] - Corporate borrowings were $1,017 million as of March 31, 2025, compared to $2,142 million as of December 31, 2024[23] Capital Structure - Partnership units outstanding were 141.0 million as of March 31, 2025, compared to 144.0 million as of December 31, 2024[30] - BBUC exchangeable shares outstanding were 71.7 million as of March 31, 2025, compared to 73.0 million as of December 31, 2024[30] - The company invested approximately $140 million to repurchase 5.9 million of its units and shares at an average price of approximately $24 per unit and share during the quarter and subsequent to quarter end[22]

Core Viewpoint - Select Medical Holdings Corporation reported a 2.4% increase in revenue for Q1 2025, alongside a significant rise in net income from continuing operations, indicating a positive financial trajectory despite challenges in certain segments [2][12]. Financial Performance - Revenue for Q1 2025 reached $1,353.2 million, up from $1,321.2 million in Q1 2024 [2]. - Income from continuing operations before other income and expense was $112.7 million, a decrease from $118.5 million year-over-year [2]. - Net income from continuing operations increased by 21.5% to $74.7 million compared to $61.5 million in the prior year [2]. - Adjusted EBITDA for Q1 2025 was $151.4 million, down from $165.8 million in Q1 2024 [2]. - Earnings per share from continuing operations rose by 33.3% to $0.44, compared to $0.33 in the same quarter last year [2]. Segment Performance - **Critical Illness Recovery Hospital Segment**: Revenue decreased by 2.9% to $637.0 million, with Adjusted EBITDA down 25.3% to $86.6 million [5][23]. - **Rehabilitation Hospital Segment**: Revenue increased by 15.7% to $307.4 million, with Adjusted EBITDA rising by 14.7% to $70.4 million [6][23]. - **Outpatient Rehabilitation Segment**: Revenue increased by 1.4% to $307.3 million, while Adjusted EBITDA slightly decreased to $24.3 million [7][24]. Company Overview - Select Medical operates 104 critical illness recovery hospitals, 35 rehabilitation hospitals, and 1,911 outpatient rehabilitation clinics across 40 states and the District of Columbia as of March 31, 2025 [4]. Dividend and Stock Repurchase - The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about May 29, 2025 [8]. - A stock repurchase program was authorized for up to $1.0 billion, with 649,804 shares repurchased at a cost of approximately $11.4 million during Q1 2025 [10][11]. Business Outlook - For fiscal year 2025, Select Medical expects revenue between $5.3 billion and $5.5 billion, Adjusted EBITDA between $510 million and $530 million, and fully diluted earnings per share between $1.09 and $1.19 [12].

Centene (CNC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Wall Street analysts expect IQVIA Holdings (IQV) to post quarterly earnings of $2.63 per share in its upcoming report, which indicates a year-over-year increase of 3.5%. Revenues are expected to be $3.77 billion, up 0.9% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefr ...

Core Insights - QuadMed, a subsidiary of Quad, Inc., has been recognized as the 2025 Best in KLAS in the Employer-Sponsored Health Care Services category, highlighting its commitment to enhancing health care experiences through improved outcomes and cost reduction [1][2][3] Company Overview - QuadMed is evolving from a provider of worksite health and wellness solutions to a comprehensive health care experience company, emphasizing whole-person care and relationship-driven services [2][4] - The company has over 30 years of experience in partnering with employers to provide direct access to health care for employees and their families, focusing on improving health, productivity, and cost efficiency [6] Brand Evolution - The new brand reflects QuadMed's commitment to removing barriers in health care access and delivering better outcomes for both members and employers [4][5] - The brand evolution is described as a reaffirmation of the company's identity and future direction, aiming to expand its reach to more employers nationwide [5] Recognition and Validation - The KLAS award serves as external validation of QuadMed's mission to innovate and deliver value in health care, emphasizing the importance of excellence in the evolving health care landscape [3][11] - KLAS recognizes organizations that excel in delivering value and innovation, underscoring the significance of QuadMed's achievement in this competitive field [3]

Financial Data and Key Metrics Changes - Total company revenues increased by 2.6% to $255 million, or 4.4% on a constant currency basis compared to Q1 2024 [6][13] - Adjusted EBITDA increased by 8.8% to $122 million, equating to an 11.2% growth rate on a constant currency basis [6][14] - Adjusted EPS improved to $0.14, a $0.01 increase versus the same period last year [6][15] - Net loss on a GAAP basis was $13 million, or $0.05 per diluted share, compared to a net income of $6 million, or $0.02 per diluted share in Q1 2024 [15] Business Line Data and Key Metrics Changes - **Sterigenics**: Revenue grew by 1.9% to $170 million, or 3.9% on a constant currency basis, with a segment income increase of 2.5% to $88 million [16] - **Nordion**: Revenue surged by 36% to $33 million, or 40.6% on a constant currency basis, with segment income increasing approximately 62% to $17.4 million [16][17] - **Nelson Labs**: Revenue declined by 9.3% to $52 million, but segment income increased by 7% to $60 million, driven by favorable volume and mix from improved core lab testing [18] Market Data and Key Metrics Changes - The Sterigenics segment operates in a $4.5 billion sterilization service addressable market, benefiting from trends such as an aging population and increased healthcare spending [7] - Nordion's revenue was positively impacted by the shift of Cobalt 60 shipments from Q2 to Q1, affecting second quarter revenues but leaving the full year outlook unchanged [7] Company Strategy and Development Direction - The company aims for revenue growth in the range of 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis for 2025 [9][20] - Focus areas include excellence in customer service, growth in key markets, operational excellence to enhance free cash flow, and disciplined capital deployment [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding volume improvements in Sterigenics and Nelson Labs, with strong customer survey results indicating positive trends [34][45] - The company does not expect current tariff policies to materially impact its business, with 85% of total revenue being service-based [9][21] Other Important Information - The company has $715 million in available liquidity, including over $300 million in unrestricted cash [19] - Capital expenditures for 2025 are projected to be between $190 million and $210 million, with a goal of generating $500 million to $600 million in free cash flow over the next three years [24][25] Q&A Session Summary Question: Impact of tariffs on the business - Management is confident that current regulations will not have a material impact, particularly regarding cobalt shipments from Canada [30] Question: Volume recovery in Sterigenics and Nelson Labs - Management is optimistic about continued volume improvements, supported by strong customer relationships and survey results [34][45] Question: Nelson Labs margin trends - Management highlighted that new regulations and increased sterilization volumes are driving margin improvements [39] Question: Legal strategy and ongoing cases - Management is confident in their defense strategy and believes they can prove their compliance and safety in court [48][50] Question: Cross-selling initiatives between Nelson and Sterigenics - Management noted ongoing incentives for cross-selling and positive customer responses to integrated services [51][54] Question: Pricing dynamics in Sterigenics - Management indicated that pricing remains stable, with ongoing discussions with customers about value and pricing adjustments [76][78]

Valuation Metrics - The price-to-earnings (P/E) ratio is a common valuation metric, but for companies with losses or minimal profits, the price-to-sales (P/S) ratio is more effective in identifying undervalued stocks [1] - The price-to-book (P/B) ratio is another useful tool for identifying low-priced stocks with high growth potential, calculated by dividing the stock's current price by its book value per share [2][6] Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [4][5] - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued, while a ratio above one may indicate overvaluation [6][7] Stock Examples - Centene Corporation (CNC) is a diversified healthcare company with a projected 3-5 year EPS growth rate of 11.5%, currently holding a Zacks Rank of 2 and a Value Score of A [16][17] - Pediatrix Medical Group (MD) provides specialized physician services with a projected EPS growth rate of 9.5% and also holds a Zacks Rank of 2 and a Value Score of A [18][19] - Pfizer (PFE), a major pharmaceutical company, has a projected EPS growth rate of 13.8% and maintains a Zacks Rank of 2 and a Value Score of A [19] - StoneCo (STNE) offers financial technology solutions with a projected EPS growth rate of 26.3%, holding a Zacks Rank of 1 and a Value Score of B [20] - Banco Santander (SAN), the largest bank in Spain, has a projected EPS growth rate of 9.6% and a Zacks Rank of 2 with a Value Score of A [21][22] Screening Parameters - Stocks with a P/B ratio less than the industry median indicate potential for price appreciation [12] - A P/S ratio lower than the industry average makes a stock more attractive [12] - A P/E ratio (F1) below the industry median is considered favorable [13] - A PEG ratio of less than 1 suggests that a stock is undervalued relative to its growth prospects [14] - Stocks should have a minimum trading price of $5 and an average 20-day volume of at least 100,000 for better liquidity [15]

Tenet Healthcare (THC) Q1 2025 Earnings Call April 29, 2025 03:01 PM ET Speaker0 Good morning, and welcome to Tenant Healthcare's First Quarter twenty twenty five Earnings Conference Call. After the speakers' remarks, there will be a question and answer session for industry analysts. I'll now turn the call over to your host, Mr. Will McDowell, Vice President, Investor Relations. Mr. McDowell, you may begin. Speaker1 Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice Pre ...

Tenet Healthcare (THC) reported $5.22 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 2.7%. EPS of $4.36 for the same period compares to $3.22 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $5.14 billion, representing a surprise of +1.64%. The company delivered an EPS surprise of +40.19%, with the consensus EPS estimate being $3.11.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...